| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
SPC primarily targets the OGR1 receptor (also known as GPR68), a proton-sensing G-protein-coupled receptor. Functional studies demonstrate that D-erythro-SPC activates OGR1 and triggers anti-inflammatory protein cascades. SPC also modulates the ryanodine receptor/calcium-release channel of cardiac sarcoplasmic reticulum membranes. The compound has been shown to bind to S1P1, S1P3, and S1P2 receptors, with L-threo-SPC acting as a potent agonist at these receptors with EC50 values of 19.3 nM, 131.8 nM, and other values.
|
|---|---|
| ln Vitro |
In vitro, SPC has been shown to promote delayed phosphorylation of Smad2 and enhance α-SMA expression. It activates the TRPM3 channel and demonstrates anti-apoptotic properties. SPC induces the release of calcium from cardiac sarcoplasmic reticulum membranes, which is a critical event in cardiac muscle contraction. The compound's effects on OGR1 activation and downstream signaling pathways have been characterized in various cell-based assays. SPC also shows benefits in cardiac hypertrophy and wound healing models.
|
| ln Vivo |
In vivo, SPC is a naturally occurring lipid mediator in blood plasma. It has been shown to have benefits in cardiac hypertrophy and wound healing. SPC modulates cardiac function through its effects on the ryanodine receptor and calcium release. The compound's anti-inflammatory properties are mediated through OGR1 activation, triggering anti-inflammatory protein cascades. Its role as a bioactive lipid mediator suggests involvement in various physiological and pathological processes.
|
| Enzyme Assay |
In vitro receptor binding assays for SPC typically involve measuring its affinity for OGR1/GPR68 using radioligand binding or functional assays. The dissociation constant (Kd) of 33.3 nM for OGR1 binding has been determined using such methods. Functional assays measure OGR1 activation by monitoring inositol phosphate formation or calcium mobilization in cells expressing the receptor. Competitive binding assays can differentiate between D-erythro-SPC and L-threo-SPC stereoisomers.
|
| Cell Assay |
In vitro cellular assays for SPC use various cell types including cardiac myocytes, fibroblasts, and immune cells. Cells are treated with SPC at concentrations ranging from nanomolar to micromolar. Endpoints include measurement of Smad2 phosphorylation, α-SMA expression, TRPM3 channel activity, and calcium release. Anti-apoptotic effects are assessed by measuring cell viability and apoptosis markers. Wound healing assays using scratch or transwell migration models evaluate SPC's effects on cell migration and tissue repair.
|
| Animal Protocol |
In vivo animal studies for SPC typically involve administration to rodent models to evaluate its effects on cardiac function, wound healing, and inflammation. Doses and routes of administration vary depending on the study. Cardiac function is assessed by echocardiography or invasive hemodynamic measurements. Wound healing is evaluated using excisional wound models. Inflammatory markers and tissue histology are assessed to evaluate the compound's effects. SPC's role as a lipid mediator makes it relevant to various disease models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for SPC are limited. As a naturally occurring lipid mediator, SPC is present in blood plasma at physiological concentrations. Its metabolism involves hydrolysis by lipid phosphatases and degradation by sphingolipid metabolic pathways. SPC binds to plasma proteins and is distributed to tissues via circulation. Detailed pharmacokinetic parameters such as half-life, volume of distribution, and clearance are not well characterized in the literature. The compound's rapid metabolism limits its systemic exposure.
|
| Toxicity/Toxicokinetics |
Toxicological data for SPC are limited. As a naturally occurring lipid mediator, SPC is present in the body at physiological concentrations. High concentrations may disrupt normal lipid signaling and cause adverse effects. In vitro studies have demonstrated anti-apoptotic properties, suggesting potential protective effects. However, dysregulation of sphingolipid signaling has been implicated in various diseases. Standard toxicological assessments for SPC as a research compound are not well documented.
|
| References | |
| Additional Infomation |
Sphingosine-1-phosphocholine is a phosphosphingolipid composed of a sphingosine molecule with a phosphocholine group attached to its primary hydroxyl group. It is a phosphosphingolipid belonging to the phosphocholine class of compounds and is also an ammonium betaine. Functionally, it is related to sphingosine. It is the conjugate base of sphingosine phosphocholine acid and sphingosine-1-phosphocholine (1+).
SPC is a bioactive lipid mediator and research tool for studying sphingolipid signaling, GPCR biology, and cardiac function. It is a ligand for OGR1/GPR68, a proton-sensing GPCR. The compound's effects on Smad2 phosphorylation, α-SMA expression, and TRPM3 channel activation make it useful for studying fibrosis, hypertrophy, and ion channel regulation. SPC is also used to study calcium signaling in cardiac muscle. It is not approved as a therapeutic drug but serves as a valuable research tool. |
| Molecular Formula |
C23H49N2O5P
|
|---|---|
| Molecular Weight |
464.62
|
| Exact Mass |
464.337
|
| CAS # |
1670-26-4
|
| PubChem CID |
9847290
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
90-102ºC
|
| LogP |
2.66
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
31
|
| Complexity |
489
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCC/C=C/C(C(COP(OCC[N+](C)(C)C)(=O)[O-])N)O
|
| InChi Key |
JLVSPVFPBBFMBE-HXSWCURESA-N
|
| InChi Code |
InChI=1S/C23H49N2O5P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(26)22(24)21-30-31(27,28)29-20-19-25(2,3)4/h17-18,22-23,26H,5-16,19-21,24H2,1-4H3/b18-17+/t22-,23+/m0/s1
|
| Chemical Name |
[(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol :~15 mg/mL (~32.28 mM; with heating and sonication.)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1523 mL | 10.7615 mL | 21.5230 mL | |
| 5 mM | 0.4305 mL | 2.1523 mL | 4.3046 mL | |
| 10 mM | 0.2152 mL | 1.0761 mL | 2.1523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
